OpGen (OPGN) Competitors $0.04 +0.00 (+0.77%) As of 07/25/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsSEC FilingsShort InterestTrendsBuy This Stock OPGN vs. XGN, DCGO, EUDA, SERA, QIPT, CORBF, NAKA, KDLY, ATPC, and BNRShould you be buying OpGen stock or one of its competitors? The main competitors of OpGen include Exagen (XGN), DocGo (DCGO), EUDA Health (EUDA), Sera Prognostics (SERA), Quipt Home Medical (QIPT), Global Cord Blood (CORBF), KindlyMD (NAKA), Kindly MD (KDLY), Agape ATP (ATPC), and Burning Rock Biotech (BNR). These companies are all part of the "healthcare" industry. OpGen vs. Its Competitors Exagen DocGo EUDA Health Sera Prognostics Quipt Home Medical Global Cord Blood KindlyMD Kindly MD Agape ATP Burning Rock Biotech Exagen (NASDAQ:XGN) and OpGen (NASDAQ:OPGN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk. Do institutionals & insiders have more ownership in XGN or OPGN? 75.3% of Exagen shares are owned by institutional investors. Comparatively, 2.7% of OpGen shares are owned by institutional investors. 12.6% of Exagen shares are owned by company insiders. Comparatively, 43.8% of OpGen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media prefer XGN or OPGN? In the previous week, Exagen had 8 more articles in the media than OpGen. MarketBeat recorded 8 mentions for Exagen and 0 mentions for OpGen. Exagen's average media sentiment score of 0.58 beat OpGen's score of 0.00 indicating that Exagen is being referred to more favorably in the media. Company Overall Sentiment Exagen Positive OpGen Neutral Is XGN or OPGN more profitable? Exagen has a net margin of -27.34% compared to OpGen's net margin of -1,140.36%. OpGen's return on equity of 0.00% beat Exagen's return on equity.Company Net Margins Return on Equity Return on Assets Exagen-27.34% -133.69% -34.87% OpGen -1,140.36%N/A -287.58% Which has more risk & volatility, XGN or OPGN? Exagen has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500. Comparatively, OpGen has a beta of -1.66, suggesting that its stock price is 266% less volatile than the S&P 500. Which has higher valuation and earnings, XGN or OPGN? Exagen has higher revenue and earnings than OpGen. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExagen$56.72M2.73-$15.11M-$0.84-8.65OpGen$2.67M0.15-$32.67MN/AN/A Do analysts prefer XGN or OPGN? Exagen presently has a consensus price target of $9.00, suggesting a potential upside of 23.80%. Given Exagen's stronger consensus rating and higher probable upside, equities research analysts clearly believe Exagen is more favorable than OpGen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exagen 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00OpGen 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryExagen beats OpGen on 12 of the 14 factors compared between the two stocks. Get OpGen News Delivered to You Automatically Sign up to receive the latest news and ratings for OPGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OPGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OPGN vs. The Competition Export to ExcelMetricOpGenMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$396K$812K$5.70B$9.50BDividend YieldN/AN/A4.58%4.01%P/E RatioN/AN/A28.4120.08Price / Sales0.150.99432.3189.32Price / CashN/AN/A36.2258.56Price / Book0.000.118.675.88Net Income-$32.67M-$27.68M$3.25B$258.89M7 Day PerformanceN/AN/A4.25%3.71%1 Month PerformanceN/AN/A10.51%11.72%1 Year PerformanceN/AN/A35.68%18.01% OpGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OPGNOpGenN/A$0.04+0.8%N/A-98.7%$396K$2.67M0.00100XGNExagen4.1808 of 5 stars$6.97-0.4%$7.50+7.6%+258.1%$149.10M$55.64M-8.30220News CoverageUpcoming EarningsAnalyst ForecastDCGODocGo2.059 of 5 stars$1.42-0.7%$3.56+150.7%-58.9%$145.84M$616.55M-71.004,407News CoveragePositive NewsEUDAEUDA Health0.9069 of 5 stars$3.09-1.9%N/A-17.8%$117.23M$4.01M0.002Upcoming EarningsGap DownSERASera Prognostics0.7237 of 5 stars$2.92flatN/A-59.5%$110M$80K-3.11120QIPTQuipt Home Medical2.9902 of 5 stars$2.02-3.3%$2.85+41.1%-40.7%$90.80M$245.91M-9.621,200CORBFGlobal Cord BloodN/A$0.55+0.1%N/A-47.4%$66.91M$196.12M0.001,200Gap UpNAKAKindlyMDN/A$10.95-0.6%N/AN/A$66.45M$2.72M-14.22N/AKDLYKindly MDN/A$11.02-3.6%N/A+453.3%$66.36M$2.47M-14.31N/AATPCAgape ATP0.8595 of 5 stars$1.30+0.8%N/A-40.8%$64.51M$1.32M-2.1740Positive NewsBNRBurning Rock Biotech1.6415 of 5 stars$4.93+4.8%N/A+0.9%$50.58M$70.67M-2.611,390Positive News Related Companies and Tools Related Companies XGN Competitors DCGO Competitors EUDA Competitors SERA Competitors QIPT Competitors CORBF Competitors NAKA Competitors KDLY Competitors ATPC Competitors BNR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OPGN) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trill...Stansberry Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OpGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OpGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OPGN Stock Alerts